Claims for Patent: 10,028,935

Summary for Patent: 10,028,935

Title:	Stabilized multi-functional antioxidant compounds and methods of use
Abstract:	Disclosed are novel stable compounds having anti-oxidant properties and methods of using the compounds for the treatment of diseases or injuries associated with oxidative stress.
Inventor(s):	Bailie; Marc (Machester, MI), Duddy; Steven K. (Ann Arbor, MI), Herman; Jim (Grass Lake, MI)
Assignee:	XPD Holdings, LLC (Ann Arbor, MI)
Application Number:	15/420,641
Patent Claims:	1. A method of treating a disease, injury, or condition, associated with reduced antioxidant levels and/or increased oxygen radical generation comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula I: ##STR00066## or a pharmaceutically acceptable salt thereon wherein: R is H, C.sub.1-6 alkyl, or C.sub.1-6 alkoxy; R.sup.1 and R.sup.2 are each independently H, C.sub.1-6 alkyl, or --C(.dbd.O)R.sup.3; R.sup.3 is optionally C.sub.1-6 alkyl or C.sub.1-6 alkoxy; L is (CH.sub.2).sub.m--; L.sup.1 is --CH(R.sup.5)-- or --C(.dbd.O)--; L.sup.2 is --O-- or --NH--; R.sup.4 is H or C.sub.1-6 alkyl; R.sup.5 is H, --C(O)OH, or --C(.dbd.O)L.sup.2 R.sup.7; R.sup.6 is H, or --(CH.sub.2).sub.nC(.dbd.O)R.sup.8; R.sup.7 is H, C.sub.1-6 alkyl, or --(CH.sub.2).sub.pC(.dbd.O)OH; R.sup.8 is --OH, --CH.sub.3, --CH.sub.2C(.dbd.O)OH, or --(CH.sub.2).sub.w--CH(NH.sub.2)--C(.dbd.O)OH; m is 1, 2, 3, or 4; and n, p, and w are each independently 0, 1, 2, 3, or 4. 2. The method according to claim 1, wherein the disease, injury or condition is a cardiovascular disease, cerebral palsy; a liver disease, cystic fibrosis, dementia, an inflammatory disease, amyotrophic lateral sclerosis, acute respiratory distress syndrome, an infectious disease, lupus, an eye disorder, multiple sclerosis, kidney disease, neuropathy, encephalopathy, diabetes, beta thalassemia, sickle cell disease, Parkinson's disease, pulmonary fibrosis, a reproductive disease, infertility, a seizure disorder, sepsis, stroke, gangrene, toxic shock, spontaneous hemolysis, hemolysis induced by chemical agents, or a traumatic insult. 3. The method according to claim 2, wherein a) the cardiovascular disease is atherosclerosis, myocardial infarction, chronic obstructive pulmonary disease, or chronic heart failure; b) the inflammatory disease is inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, or colitis; c) the liver disease is cirrhosis or hepatitis; d) the hemolysis induced by chemical agents is hemolysis induced by anti-malarial treatment or hemolysis induced by chemotherapy treatment; or e) the eye disorder is cataracts or macular degeneration. 4. The method according to claim 2, wherein the traumatic insult is exposure to bioweapons, a chemical burn, a heat burn, contrast-induced nephropathy, a drug overdose, radiation exposure, exposure to cigarette smoke, exposure to toxic gas, blast injury, a contact sensitivity reaction, a delayed hypersensitivity reaction, is an insult that results in hearing loss, envenomation, sunburn, transplant rejection, gunshot, compression injury, toxicodendrin species associated inflammation, skin damage, or chemotherapy treatment. 5. The method according to claim 4, wherein the traumatic insult is a) an exposure to a bioweapon, and the bioweapon is ricin, Bacillus anthracis, ebola virus, Clostridium botulinum, or nipah virus; b) a blast injury: or c) a drug overdose and the drug overdose is an overdose of acetaminophen or morphine. 6. The method according to claim 1, wherein the compound is selected from: (2S)--S-2,3-diamino-3-oxopropyl 2-(3-aminopropanamido)-3-(1H-imidazol-5-yl) propanethioate; 2-amino-3-((S)-2-(3-aminopropanamido)-3-(1H-imidazol-5-yl)propanoylthio)p- ropanoic acid; 2-acetamido-3-((S)-2-(3-aminopropanamido)-3-(1H-imidazol-5-yl)propanoylth- io) propanoic acid; (2S)--S-2-acetamido-3-amino-3-oxopropyl2-(3-aminopropanamido)-3-(1H-imida- zol-5-yl) propanethioate; methyl 2-acetamido-3-((S)-2-(3-aminopropanamido)-3-(1H-imidazol-5-yl) propanoylthio)propanoate; 2-(2-((S)-2-(3-aminopropanamido)-3-(1H-imidazol-5-yl)propanoylthio)propan- amido) acetic acid; (S)--S-2-aminoethyl 2-(3-aminopropanamido)-3-(1H-imidazol-5-yl)propanethioate (7); 2-amino-5-(2-((S)-2-(3-aminopropanamido)-3-(1H-imidazol-5-yl)propanoylthi- o)-1-carboxy ethylamino)-5-oxopentanoic acid; 2-amino-5-(3-((S)-2-(3-aminopropanamido)-3-(1H-imidazol-5-yl)propanoylthi- o)-1-(carboxy methylamino)-1-oxopropan-2-ylamino)-5-oxopentanoic acid; (2S)--S-2,3-diamino-3-oxopropyl 2-(3-acetamidopropanamido)-3-(1H-imidazol-5-yl) propanethioate; 3-((S)-2-(3-acetamidopropanamido)-3-(1H-imidazol-5-yl)propanoylthio)-2-am- inopropanoic acid; (8S)-8-((1H-imidazol-5-yl)methyl)-2,7,10,14-tetraoxo-6-thia-3,9,13-triaza- pentadecane-4-carboxylic acid; (2S)--S-2-acetamido-3-amino-3-oxopropyl 2-(3-acetamidopropanamido)-3-(1H-imidazol-5-yl)propanethioate; (8S)-methyl 8-((1H-imidazol-5-yl)methyl)-2,7,10,14-tetraoxo-6-thia-3,9,13-triazapenta- decane-4-carboxylate; 2-(2-{[(2S)-2-(3-acetamidopropanamido)-3-(1H-imidazol-5-yl)propanoyl]sulf- anyl} propanamido)acetic acid; (S)--S-2-aminoethyl 2-(3-acetamidopropanamido)-3-(1H-imidazol-5-yl)propanethioate; 2-amino-4-[(1-carboxy-2-{[(2S)-2-(3-acetamidopropanamido)-3-(1H-imidazol-- 5-yl) propanoyl]sulfanyl}ethyl)carbamoyl] butanoic acid; 2-amino-4-({1-[(carboxymethyl)carbamoyl]-2-{[(2S)-2-(3-acetamidopropanami- do)-3-(1H-imidazol-5-yl)propanoyl]sulfanyl}ethyl}carbamoyl)butanoic acid; (2S)--S-2,3-diamino-3-oxopropyl 2-(4-aminobutanamido)-3-(1H-imidazol-5-yl) propanethioate; 2-amino-3-((S)-2-(4-aminobutanamido)-3-(1H-imidazol-5-yl)propanoylthio) propanoic acid; 2-acetamido-3-((S)-2-(4-aminobutanamido)-3-(1H-imidazol-5-yl)propanoylthi- o) propanoic acid; (2S)--S-2-acetamido-3-amino-3-oxopropyl 2-(4-aminobutanamido)-3-(1H-imidazol-5-yl) propanethioate; methyl 2-acetamido-3-((S)-2-(4-aminobutanamido)-3-(1H-imidazol-5-yl) propanoylthio)propanoate; 2-(2-((S)-2-(4-aminobutanamido)-3-(1H-imidazol-5-yl)propanoylthio)propana- mido) acetic acid; (S)--S-2-aminoethyl 2-(4-aminobutanamido)-3-(1H-imidazol-5-yl) propanethioate; 2-amino-5-(2-((S)-2-(4-aminobutanamido)-3-(1H-imidazol-5-yl)propanoylthio- )-1-carboxyethylamino)-5-oxopentanoic acid; 2-amino-5-(3-((S)-2-(4-aminobutanamido)-3-(1H-imidazol-5-yl) propanoylthio)-1-(carboxymethylamino)-1-oxopropan-2-ylamino)-5-oxopentano- ic acid; (2S)--S-2,3-diamino-3-oxopropyl 2-(3-aminopropanamido)-3-(1-methyl-1H-imidazol-5-yl)propanethioate; 2-amino-3-((S)-2-(3-aminopropanamido)-3-(1-methyl-1H-imidazol-5-yl)propan- oylthio) propanoic acid; 2-acetamido-3-((S)-2-(3-aminopropanamido)-3-(1-methyl-1H-imidazol-5-yl) propanoylthio)propanoic acid; (2S)--S-2-acetamido-3-amino-3-oxopropyl 2-(3-aminopropanamido)-3-(1-methyl-1H-imidazol-5-yl)propanethioate; methyl 2-acetamido-3-((S)-2-(3-aminopropanamido)-3-(1-methyl-1H-imidazol-- 5-yl) propanoylthio)propanoate; 2-(2-((S)-2-(3-aminopropanamido)-3-(1-methyl-1H-imidazol-5-yl)propanoylth- io)propanamido) acetic acid; (S)--S-2-aminoethyl 2-(3-aminopropanamido)-3-(1-methyl-1H-imidazol-5-yl) propanethioate; 2-amino-5-(2-((S)-2-(3-aminopropanamido)-3-(1-methyl-1H-imidazol-5-yl)pro- panoylthio)-1-carboxyethylamino)-5-oxopentanoic acid; 2-amino-5-(3-((S)-2-(3-aminopropanamido)-3-(1-methyl-1H-imidazol-5-yl) propanoylthio)-1-(carboxymethylamino)-1-oxopropan-2-ylamino)-5-oxopentano- ic acid; 2-amino-4-({1-[(carboxymethypcarbamoyl]-2-{[(2S)-2-(3-acetamidopr- opanamido)-3-(1-butyl-1H-imidazol-5-yl)propanoyl]sulfanyl}ethyl}carbamoyl)- butanoic acid; 2-amino-5-(3-((S)-2-(4-aminobutanamido)-3-(1-propyl-1H-imidazol-5-yl) propanoylthio)-1-(carboxymethylamino)-1-oxopropan-2-ylamino)-5-oxopentano- ic acid; (S)--S--((R)-2-acetamido-3-amino-3-oxopropyl)-2-(3-aminopropanami- do)-3-(1H-imidazol-5-yl)propanethioate; and (R)-methyl 2-acetamido-3-(((S)-2-(3-aminopropanamido)-3-(1H-imidazol-5-yl) propanoyl)thio)propanoate. 7. The method according to claim 6, wherein the disease, injury or condition is a cardiovascular disease, cerebral palsy, a liver disease, cystic fibrosis, dementia, an inflammatory disease, amyotrophic lateral sclerosis, acute respiratory distress syndrome, an infectious disease, lupus, an eye disorders, multiple sclerosis, kidney disease, neuropathy, encephalopathy, diabetes, beta thalassemia, sickle cell disease, Parkinson's disease, pulmonary fibrosis, a reproductive disease, infertility, a seizure disorder, sepsis, stroke, gangrene, toxic shock, spontaneous hemolysis, hemolysis induced by chemical agents, or a traumatic insult. 8. The method according to claim 7, wherein a) the cardiovascular disease is atherosclerosis, myocardial infarction, chronic obstructive pulmonary disease, or chronic heart failure; b) the inflammatory disease is inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, or colitis; c) the liver disease is cirrhosis or hepatitis; d) the hemolysis induced by chemical agents is hemolysis induced by anti-malarial treatment or hemolysis induced by chemotherapy treatment; or e) the eye disorder is cataracts or macular degeneration. 9. The method according to claim 7, wherein the traumatic insult is exposure to bioweapons, a chemical burn, a heat burn, contrast-induced nephropathy, a drug overdose, radiation exposure, exposure to cigarette smoke, exposure to toxic gas, blast injury, a contact sensitivity reaction, a delayed hypersensitivity reaction, is an insult that results in hearing loss, envenomation, sunburn, transplant rejection, gunshot, compression injury, toxicodendrin species associated inflammation, skin damage, or chemotherapy treatment. 10. The method according to claim 9, wherein the traumatic insult is] a) an exposure to a bioweapon, and the bioweapon is ricin, Bacillus anthracis, ebola virus, Clostridium botulinum, or nipah virus; or b) a blast injury. 11. The method according to claim 9, wherein the drug overdose is an overdose of acetaminophen or morphine. 12. A method of treating a disease, injury, or condition, associated with reduced antioxidant levels and/or increased oxygen radical generation comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula II: ##STR00067## or a pharmaceutically acceptable salt thereof wherein: L is --(CH.sub.2).sub.m--; L.sup.1 is --CH(R.sup.5)-- or --C(.dbd.O)--; L.sup.2 is --O-- or --NH--; R.sup.4 is H or C.sub.1-6 alkyl; R.sup.5 is H, --C(O)OH, or --C(.dbd.O)L.sup.2 R.sup.7; R.sup.6 is H, or --(CH.sub.2).sub.nC(.dbd.O)R.sup.8; R.sup.7 is H, C.sub.1-6 alkyl, or --(CH.sub.2).sub.pC(.dbd.O)OH; R.sup.8 is --OH, --CH.sub.3, --CH.sub.2C(.dbd.O)OH, or --(CH.sub.2).sub.w--CH(NH.sub.2)--C(.dbd.O)OH; R.sup.9 is H, C.sub.1-6 alkyl, or --C(.dbd.O) C.sub.1-6 alkyl; m is 1, 2, 3, or 4; and n, p, and w are each independently 0, 1, 2, 3, or 4. 13. The method according to claim 12, wherein the disease, injury or condition is a cardiovascular disease, cerebral palsy; a liver disease, cystic fibrosis, dementia, an inflammatory disease, amyotrophic lateral sclerosis, acute respiratory distress syndrome, an infectious disease, lupus, an eye disorder, multiple sclerosis, kidney disease, neuropathy, encephalopathy, diabetes, beta thalassemia, sickle cell disease, Parkinson's disease, pulmonary fibrosis, a reproductive disease, infertility, a seizure disorder, sepsis, stroke, gangrene, toxic shock, spontaneous hemolysis, hemolysis induced by chemical agents, or a traumatic insult. 14. The method according to claim 13, wherein a) the cardiovascular disease is atherosclerosis, myocardial infarction, chronic obstructive pulmonary disease, or chronic heart failure; b) the inflammatory disease is inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, or colitis; c) the liver disease is cirrhosis or hepatitis; d) the hemolysis induced by chemical agents is hemolysis induced by anti-malarial treatment or hemolysis induced by chemotherapy treatment; or e) the eye disorder is cataracts or macular degeneration. 15. The method according to claim 13, wherein the traumatic insult is exposure to bioweapons, a chemical burn, a heat burn, contrast-induced nephropathy, a drug overdose, radiation exposure, exposure to cigarette smoke, exposure to toxic gas, blast injury, a contact sensitivity reaction, a delayed hypersensitivity reaction, is an insult that results in hearing loss, envenomation, sunburn, transplant rejection, gunshot, compression injury, toxicodendrin species associated inflammation, skin damage, or chemotherapy treatment. 16. The method according to claim 15, wherein the traumatic insult is a) an exposure to a bioweapon, and the bioweapon is ricin, Bacillus anthracis, ebola virus, Clostridium botulinum, or nipah virus; b) a blast injury; or c) a drug overdose and the drug overdose is an overdose of acetaminophen or morphine. 17. The method according to claim 12, wherein the compound is selected from: (2R)-4-(2-acetamido-2-carboxyethylthio)-2-hydroxy-N,N,N-trimethyl-4- -oxobutan-1-aminium; (2R)-4-(2-acetamido-3-amino-3-oxopropylthio)-2-hydroxy-N,N,N-trimethyl-4-- oxobutan-1-aminium; (2R)-4-(2-acetamido-2-carboxyethylthio)-2-acetoxy-N,N,N-trimethyl-4-oxobu- tan-1-aminium; (2R)-4-(2-acetamido-3-amino-3-oxopropylthio)-2-acetoxy-N,N,N-trimethyl-4-- oxobutan-1-aminium; (2R)-4-(2-acetamido-2-carboxyethylthio)-N,N,N-trimethyl-4-oxo-2-(propiony- loxy)butan-1-aminium; (2R)-4-(2-acetamido-3-amino-3-oxopropylthio)-N,N,N-trimethyl-4-oxo-2-(pro- pionyloxy)butan-1-aminium. 18. The method according to claim 17, wherein the disease, injury or condition is a cardiovascular disease, cerebral palsy; a liver disease, cystic fibrosis, dementia, an inflammatory disease, amyotrophic lateral sclerosis, acute respiratory distress syndrome, an infectious disease, lupus, an eye disorder, multiple sclerosis, kidney disease, neuropathy, encephalopathy, diabetes, beta thalassemia, sickle cell disease, Parkinson's disease, pulmonary fibrosis, a reproductive disease, infertility, a seizure disorder, sepsis, stroke, gangrene, toxic shock, spontaneous hemolysis, hemolysis induced by chemical agents, or a traumatic insult. 19. The method according to claim 18, wherein, a) the cardiovascular disease is atherosclerosis, myocardial infarction, chronic obstructive pulmonary disease, or chronic heart failure; b) the inflammatory disease is inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, or colitis; c) the liver disease is cirrhosis or hepatitis; d) the hemolysis induced by chemical agents is hemolysis induced by anti-malarial treatment or hemolysis induced by chemotherapy treatment; or e) the eye disorder is cataracts or macular degeneration. 20. The method according to claim 18, wherein the traumatic insult is exposure to bioweapons, a chemical burn, a heat burn, contrast-induced nephropathy, a drug overdose, radiation exposure, exposure to cigarette smoke, exposure to toxic gas, blast injury, a contact sensitivity reaction, a delayed hypersensitivity reaction, is an insult that results in hearing loss, envenomation, sunburn, transplant rejection, gunshot, compression injury, toxicodendrin species associated inflammation, skin damage, or chemotherapy treatment. 21. The method according to claim 20, wherein the traumatic insult is a) an exposure to a bioweapon, and the bioweapon is ricin, Bacillus anthracis, ebola virus, Clostridium botulinum, or nipah virus; or b) a blast injury. 22. The method according to claim 20, wherein the drug overdose is an overdose of acetaminophen or morphine.

Details for Patent 10,028,935

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2032-07-10